Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Technology in Action: One Signal, Two Signals, 3D Signals

By Drug Discovery Trends Editor | August 14, 2008

FISH and automated cell image analysis reduce manual counting fatigue and errors. 

Dr. Maria Athelogou, Senior Research Scientist, Definiens AG
Prof. Joachim Diebold, Head of the Institute for Pathology at the Kantonspital Luzern, Switzerland.
Dr. Tamara Manuelian, Solution Engineer Life Sciences, Definiens AG
Dr. Guenter Schmidt, Senior Research Scientist, Definiens AG
Dr. Alexander Schipf, Assistant Physician at the Institute for Pathology at the Kantonspital Luzern, Switzerland.
Prof. Gerd Binnig is the Founder and Head of Research, Definiens AG

Even though targeted cancer medicines are expensive, they are highly effective. Personalized medicine is not just a vision for the future, it is becoming a reality for therapies such as breast cancer. However, in order to identify patients who might benefit from a particular treatment, biomarkers need to be developed.

With research for the discovery and development of biomarkers on the rise, the need for accurate methods for detection, quantification, and interpretation of the effects of biomarkers on tissue is increasing as well. Virtual or digital microscopy is used to acquire image data to describe the effect of biomarkers on biopsy tissue, with thousands of images being acquired in automated workflows. Biomarker discovery platforms and workflows are used in pharmaceutical drug discovery and development processes, producing meaningful, but enormous amounts of complex data that has to be analyzed and interpreted in a timely, reliable, and reproducible way.

Conventionally, clinical experts—such as pathologists—analyze and interpret such data in order to make decisions regarding the diagnosis and therapy of the specific cancer. Image analysis algorithms, methods, and software tools can help interpret biomarker-relevant data. 

   Definiens image analysis results for IHC Definiens image analysis results for IHC Definiens image analysis results for IHC
click to enlarge

Figure 1: Definiens image analysis results for Immunohistochemistry (IHC) that measures the HER2 protein present on the surface of the tumor cells. Normal cells are shown in blue. Cells with nuclei that show morphological similarities to cancer cell nuclei are yellow. Cells that show brown stained membrane are purple. These specimens are interpreted on a numeric scale:
0 negative for HER2 overexpression
2+   positive for HER2 overexpression
3+   positive for HER2 overexpression
(Souce: DacoCytomation)

The HER2/neu oncogene resides on chromosome 17q, encoding a transmembrane tyrosine kinase growth factor receptor. When breast cancers are present, amplification of the HER2/neu gene, or overexpression of the HER2/neu protein, can be detected. There is correlation between gene amplification and protein overexpression. 

HER2 gene amplification assessed by fluorescent in situ hybridization (FISH) may improve the predictive ability of this marker for Herceptin (trastuzumab)  therapies. Today, HER2 is assessed by the FISH method when there is an indication of equivocal immunohistochemistry (IHC) results. Figure 1 shows an example of the quantification of IHC HER2/neu breast biopsy by using object- and context-based image analysis software.1 In the case of FISH HER2/neu, the chromosome 17 centromere is marked with a green fluorescent signal, while the HER2 gene is marked with an orange or red fluorescent signal.

  undefined 
2A: click to enlarge

undefined 
2B: click to enlarge
 
undefined
2C: click to enlarge
 
Figure 2: Definiens image analysis and quantification of FISH for a cancerous breast biopsy that shows HER2/neu amplification. Optical slices are on the left. Three-dimensional object representation of signals and nuclei are on the right. The thickness of the whole probe (z-axis) is 4?m.

Figure 2A: Single signals of HER2/neu (red) and clusters (blue)
Figure 2B: Chromosome 17 signals (green)
Figure 2C: HER2/neu single signals (red) and clusters (blue) within single nuclei (yellow)
(Source: Institute of Pathology Lucern)

In conventional analysis, at least 60 or 100 non-overlapping tumor cell nuclei must be selected and the green and orange/pink signals in each cell nucleus counted. The overall gene to chromosome 17 ratio must be calculated as well. Tumor gene amplification is present when the HER2/neu-to-chromosome 17 ratio is calculated to be greater than 2.2.2 In clinical diagnosis and prognosis support, pathologists calculate this ratio manually by counting the marked chromosomes and genes (so-called “fluorescent signals”) for each nucleus of each of the 100 cells and then calculating the quotient of the gene signals to chromosome signals. A key disadvantage of this method is that due to fatigue and loss of concentration,even an experienced pathologist can overlook some of the fluorescent signals. Only small sections of the biopsy tissue of a tumor can be analyzed, also due to fatigue.

In addition, deciding whether a fluorescent signal represents a single gene or multiple overlapping genes is often subjective. When counting the same slice of a tumor biopsy, different pathologists can come up with different results.

At least three dimensions are examined during the analysis. The pathologist counts signals by changing the focus of the microscope along the z-axis, analyzing the same nuclei in different optical slices to avoid counting mistakes such as overlaps or doubles. Although digital microscopes are able to acquire digital optical slices, there are no corresponding image analysis methods to analyze signals (whether solitary or clustered) or to make calculations relative to associated nuclei, which pathologists do manually when calculating the degree of amplification in breast tumor biopsy tissue.

Traditional image processing techniques focus on pixel processing. An image analysis system from Definiens, the Definiens Cognition Network Technology  identifies objects instead of individual pixels and makes inferences about the objects by looking at them in context. This enables levels of aggregation and abstraction that mirror intuitive human understanding and deliver semantic classification based on context.

Single nuclei or clusters of nuclei, solitary fluorescent signals, as well as clustered fluorescence signals in image z-stacks, (such as stacks of optical cuts of biopsy tissue marked with FISH technology) can be analyzed. The degree of amplification can be calculated independently for each single, three-dimensional nucleus automatically. By collating these calculations, more than 100 nuclei can be analyzed automatically.3, 4 

When optical slice image data represents fluorescent signals, pixels are grouped to form objects—which form signal compartments—which in turn form nuclei, HER2/neu, and chromosome 17 signals in the nuclei (Figure 2). Algorithms enable automated counting of  three-dimensional single signals and  three-dimensional clusters of signals, distinguishing between overlapping  three-dimensional signals in  three-dimensional single nuclei. The quotient of the HER2/neu signals to the chromosome 17 signals in each of the automatically-selected single nuclei is also calculated automatically. The count, distances, and relative positions between nuclei, between signals, and between nuclei and signals can be quantified. This supports more detailed morphological quantification of the effect of FISH biomarkers on cancerous tissue.3, 4
 

About the Authors
Dr. Athelogou is one of the co-inventors of the Definiens Cognition Network Technology. She has developed computer-based monitoring and diagnostic methods, models, and simulations for complex natural systems.
Prof. Joachim Diebold is globally recognized for his outstanding work in molecular pathology.
Dr. Tamara Manuelian received her doctor’s degree in biology at the University Hamburg.
Dr. Guenter Schmidt received his doctor’s degree in physics at the Technical University Tuebingen and is one of the co-inventors of the Definiens Cognition Network Technology.
Dr. Alexander. Schipf is Assistant Physician at the Institute for Pathology at the Kantonspital Luzern, Switzerland.
Prof. Gerd Binnig is the Founder and Head of Research of Definiens. He was awarded with the Nobel Prize for Physics.

References
1.  Athelogou, M., et. al., Bildanalyse in Medizin und Biologie, E. Wintermantel and Suk-Woo Ha (Editors) Medizintechnik-Life Science Engineering, Springer 2008 (Available in English: https://www.springerlink.com/content/q5181j6111008mm5/?p=170765a9f0924c4aba2d641e6fa0d348&pi=5)

 2.  Wolff, Antonio C. et al., 2007, Vol. 25, No. 1, American Society of Clinical Oncology/College of American  Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer, Journal of Clinical Oncology

3.  Athelogou, M., et.al., June 12, 2008, Automatic Image Analysis and Quantification for Fluorescence in Situ Hybridization, US Patent Application Publication

 4.  Athelogou, M., et.al., Analyse mehrdimensionaler Bilddaten, MikrioskopieBildanalyle, Laborpraxis, May 2008

 


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE